Apricoxib is an experimental anticancer drug and nonsteroidal anti-inflammatory drug (NSAID).[1] It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly-defined models of pancreatic cancer.[2] It was also studied in clinical trials for non-small-cell lung cancer.[3] Development was abandoned in 2015 due to poor clinical trial results.[4]
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C19H20N2O3S |
Molar mass | 356.44 g·mol−1 |
3D model (JSmol) |
|
| |
|